Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Development of Silent Brain Lesions in Pediatric Patients with anti-MOG-Associated Demyelination
Child Neurology and Developmental Neurology
P12 - Poster Session 12 (12:00 PM-1:00 PM)
5-009
To compare the frequency of new asymptomatic (silent) brain lesions, and their association with clinically relapsing course in children positive for antibodies (Abs) to myelin oligodendrocyte glycoprotein (MOG), compared to children with multiple sclerosis (MS) and other MOG Abs-negative (MOG-) demyelinating diseases.

The presence of MOG Abs is associated with a monophasic or relapsing disease. The frequency of silent lesions in MOG Abs-positive (MOG+) patients is unknown, and it is unknown whether it is necessary or appropriate to monitor MOG+ patients with periodic MRI scans.
206 children with incident demyelinating syndromes (105 females, median age 11.0 years, range 3.0-17.9) were prospectively followed with clinical and serologic evaluations, and acquisition of brain MRI scans at 3, 6, 12 months from presentation, and annually thereafter (median MRI follow-up 5.0 years, range 1.00-12.1). Sixty-eight participants were MOG+ at onset, 15 of whom with clinically relapsing course, and 27/68 were persistently MOG+. The remaining (MOG- participants) had MS (n=43), relapsing transverse myelitis (n=2), or monophasic demyelinating syndromes (n=93). Only 2 MOG+ patients received disease modifying therapies, versus 34/43 MS, and none of the other MOG-negative patients.
Among MOG+ patients, 11/68 (16%) developed a total of 17 silent brain lesions. Eleven of the 17 silent lesions (65%) were detected within 1 year from presentation. Only 3/15 (20%) MOG+ patients who had subsequent attacks developed silent lesions. Conversely, 4/11 (36%)  patients with silent lesions experienced clinical relapses. Silent lesions were more common in participants with MS (40/43 patients [93%], p<0.0001), and less frequent among MOG- participants (5/95 [5%], p=0.041).

Silent lesions can occur in MOG+ patients, being more frequent in the first months following clinical presentation. They are substantially less frequent than in MS patients, but more common than in MOG- non-MS cases. Detection of silent lesions is only weakly associated with clinically relapsing disease.
Authors/Disclosures
Giulia Fadda, MD (University of Ottawa)
PRESENTER 		Dr. Fadda has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen/Horizon Therapeutics. Dr. Fadda has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for roche. Dr. Fadda has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Fadda has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Novartis.
Julia O'Mahony (The Hospital for Sick Children) Ms. O'Mahony has nothing to disclose.
Robert A. Brown, PhD (ShadowLab Reseaerch) Dr. Brown has received stock or an ownership interest from ShadowLab Research Inc.. Dr. Brown has received intellectual property interests from a discovery or technology relating to health care. Dr. Brown has a non-compensated relationship as a consultant with the Population Council that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
No disclosure on file
Giulia Longoni, MD (The Hospital for Sick Children) Dr. Longoni has nothing to disclose.
No disclosure on file
Leonard H. Verhey, PhD (The Hospital for Sick Children) No disclosure on file
E. Ann Yeh, MD, MA, FRCPC (Hospital for Sick Children) Dr. Yeh has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pipeline therapeutics. Dr. Yeh has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Yeh has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for SCN. Dr. Yeh has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. The institution of Dr. Yeh has received research support from CIHR. The institution of Dr. Yeh has received research support from National MS Society. The institution of Dr. Yeh has received research support from SickKids Foundation. The institution of Dr. Yeh has received research support from MSSC. The institution of Dr. Yeh has received research support from Garry Hurvitz Foundation. The institution of Dr. Yeh has received research support from Leong Centre. The institution of Dr. Yeh has received research support from OMSLife. The institution of Dr. Yeh has received research support from Canada's Drug Agency. Dr. Yeh has received personal compensation in the range of $0-$499 for serving as a Author with Medscape. Dr. Yeh has a non-compensated relationship as a Editorial Board with Neurology that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Yeh has a non-compensated relationship as a Editorial Board with MSJ that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
Ruth-Ann Marrie, MD, PhD (University of Manitoba) The institution of Dr. Marrie has received research support from CIHR. The institution of Dr. Marrie has received research support from MS Canada. The institution of Dr. Marrie has received research support from National MS Society. The institution of Dr. Marrie has received research support from Crohn's and Colitis Canada. The institution of Dr. Marrie has received research support from US Department of Defense. The institution of Dr. Marrie has received research support from The Arthritis Society. The institution of Dr. Marrie has received research support from CMSC.
Patrick Waters, PhD (Oxford Autoimmune Neurology Diagnostic Lab - Nuffield Clinical Neurosciences) Dr. Waters has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Waters has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB. Dr. Waters has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UBC. The institution of Dr. Waters has received research support from Guthy-Jackson Charitable Foundation. Dr. Waters has received intellectual property interests from a discovery or technology relating to health care.
Douglas L. Arnold, MD, FÂ鶹´«Ã½Ó³»­ (Montreal Neurological Institute, McGill Univ) Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BMS. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Frequency Therapeutics. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shionogi. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Xfacto communications. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Find therapeutics. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GSK. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Idorsia. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kiniksa. Dr. Arnold has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Clario.
Brenda L. Banwell, MD, FÂ鶹´«Ã½Ó³»­ (Johns Hopkins University) Dr. Banwell has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Banwell has received personal compensation in the range of $0-$499 for serving as a Consultant for UCB. Dr. Banwell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Banwell has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Banwell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Banwell has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Banwell has received research support from National MS Society. The institution of Dr. Banwell has received research support from NIH.
Amit Bar-Or, MD, FRCPC (University of Pennsylvania) Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche Genentech. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merk/EMD Serono. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving as a Consultant for cabaletta. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck/EMD Serono. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi/Genzyme. The institution of Dr. Bar-Or has received research support from Novartis. The institution of Dr. Bar-Or has received research support from Biogen. The institution of Dr. Bar-Or has received research support from Roche/Genentech.